Selecta Biosciences is narrowing its focus

Se­lec­ta Bio­sciences an­nounced Thurs­day that it will stop in­vest­ment in most of its pipeline as­sets ex­cept for a treat­ment for chron­ic re­frac­to­ry gout li­censed to Swedish phar­ma So­bi and a gene ther­a­py it’s de­vel­op­ing with Astel­las.

The com­pa­ny plans to sub­mit a BLA for SEL-212 in the first half of next year.

“While we firm­ly be­lieve that the bal­ance of our pipeline be­yond SEL-212 has the po­ten­tial to gen­er­ate mean­ing­ful re­turns for stock­hold­ers, we rec­og­nize that sig­nif­i­cant cap­i­tal and time will be re­quired to ad­vance these as­sets to val­ue cre­at­ing in­flec­tion points on our own. And as such, we have tak­en the de­ci­sion to sus­pend fur­ther in­vest­ments in all pro­grams be­yond SEL-212,” Se­lec­ta CEO Carsten Brunn said on an in­vestor call.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.